Evidence map›Paper›PMID 42626046›Full record

ArticleJCEM case reports2026

The silent catecholamine: a rapidly evolving, exclusively dopamine-secreting pheochromocytoma in a 22-year-old.

Ahlam Rozaine, Tom Claeys, Stijn Roels, Peter Coremans

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahlam RozaineDepartment of Diabetes and Endocrinology, VITAZ Hospital, Sint-Niklaas 9100, Belgium.ORCID https://orcid.org/0009-0007-0763-7388
Tom ClaeysDepartment of Urology, VITAZ Hospital, Sint-Niklaas 9100, Belgium.
Stijn RoelsDepartment of Medical and Molecular Imaging, VITAZ Hospital, Sint-Niklaas 9100, Belgium.
Peter CoremansDepartment of Diabetes and Endocrinology, VITAZ Hospital, Sint-Niklaas 9100, Belgium.ORCID https://orcid.org/0000-0002-6281-9447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors, typically secreting norepinephrine and/or epinephrine. A distinct and uncommon variant is the dopamine-secreting PPGL, often presenting asymptomatically, relatively large, and frequently extra-adrenal. Dopamine-excess may independently indicate a higher malignancy risk. We report the case of a 22-year-old man with an incidentally discovered right adrenal lesion. Biochemical evaluation revealed markedly elevated urinary dopamine and 3-methoxytyramine (3MT). Imaging showed a lipid-poor adrenal mass with minimal [18F]-fluorodeoxyglucose (FDG) avidity. Six months later, the lesion had significantly grown and increased in density, with further elevation of dopamine metabolites. The patient underwent robotic-assisted adrenalectomy following preoperative preparation with oral calcium channel blockers (CCB). Surgery was uneventful, and postoperative catecholamine levels normalized. Histopathology confirmed a pheochromocytoma without features of malignancy. This case highlights the importance of age-specific management in individuals under 40 years, even when the lesion presents benign at first. Noncontrast computed tomography (CT) remains the initial imaging modality of choice. Standard treatment consists of surgical resection. In case of dopamine excess in PPGL, CCB, rather than α-blockers, may be recommended for hemodynamic management.

Indexed as

3-methoxytyraminecalcium channel blockersdopaminepheochromocytoma and paragangliomayoung adults

Identifiers

PMID42626046
PMCPMC13490864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.